The research study is testing a new way of taking hormone tablets for prostate cancer. The new method is called ‘adaptive therapy,’ also known as a pause/restart strategy.

Trial Status
Trial Phase
Phase 2 Drug Trial
Registry Listing
ERM Project ID
Trial contact details
Contact Person
Caitlin Bennett
What you need to know

Who can take part?

Patients with Castrate Resistant Metastatic prostrate cancer.

What is involved for you?

Your doctor will prescribe  a hormone tablet for your prostate cancer. There are two similar but slightly different tablets available – abiraterone (Zytiga®), which is taken as two tablets daily (500mg each) and enzalutamide (Xtandi®), which is taken as four capsules daily (40mg each).  You will also be asked to continue your regular hormonal injections (androgen deprivation therapy (ADT)) as per your standard treatment. Half of all participants in this trial will take their hormone tablet in the standard fashion. Half will take breaks in treatment when a blood test shows that the tablets have worked to control the cancer. You will see the doctor and study nurse every four weeks for a physical exam and blood test. This blood test will monitor how the treatment is working with a PSA blood test.

All research clinical trials news

2023 was an outstanding year for Mater Research with $13.7 million in grant funding received and 424 publications recorded.



Highlighting Mater Research’s year of achievements: 2023 Annual Report

When Monique Perry was diagnosed with aggressive triple-negative breast cancer she feared her family history was about to repeat itself.



Clinical trials give Queensland breast cancer patients hope

Mater researchers in Brisbane are leading a trial of a game-changing flu vaccine that has the potential to provide greater and more durable protection against the virus.



Mater launches trial of Australian-first flu vaccine

Displaying results 1-3 (of 18)
 |<  < 1 - 2 - 3 - 4 - 5 - 6  >  >|